Royalty Pharma plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pablo Legorreta
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 110 East 59th Street New York NY United States of America 10022
- IPO Date
- Jun 16, 2020
- CIK
- 0001802768
- Website
- royaltypharma.com
- Similar Companies
- Business
- Royalty Pharma plc (Nasdaq: RPRX) operates as the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry; the company acquires royalties on sales of approved and development-stage biopharmaceutical products from originators including pharmaceutical companies, biotechnology firms, universities and research institutions. Its portfolio encompasses royalties on more than 35 marketed products and over a dozen pipeline candidates targeting diseases such as cystic fibrosis (Kalydeco, Orkambi, Symdeko, Trikafta from Vertex Pharmaceuticals), multiple sclerosis (Tysabri from Biogen, frexalimab from Sanofi), blood cancers (Imbruvica from AbbVie and Johnson & Johnson, IDHIFA from Bristol Myers Squibb), prostate cancer (Xtandi from Astellas and Pfizer, Erleada from Johnson & Johnson), ATTR amyloidosis (Amvuttra from Alnylam), spinal muscular atrophy (Evrysdi from Roche, Spinraza from Biogen), migraine (Emgality from Lilly, Nurtec ODT and Zavzpret from Pfizer), diabetes (Januvia and Onglyza from Merck, Soliqua from Sanofi), inflammatory conditions (Tremfya from Johnson & Johnson, Cimzia from UCB, Entyvio from Takeda), respiratory diseases (Trelegy Ellipta from GSK, Airsupra from AstraZeneca), and other areas including schizophrenia (Cobenfy from Bristol Myers Squibb, TEV-'749 from Teva), growth hormone deficiency (Skytrofa from Ascendis Pharma), bladder cancer (Adstiladrin from Ferring), hypoparathyroidism (Yorvipath from Ascendis), low-grade glioma (Voranigo from Servier), chronic graft-versus-host disease (Niktimvo from Syndax and Incyte), and myelodysplastic syndromes (Rytelo from Geron); pipeline royalties include obexelimab for immunoglobulin G4-related disease from Zenas BioPharma, Imdelltra for small cell lung cancer from Amgen, daraxonrasib for RAS mutant pancreatic cancer from Revolution Medicines, litifilimab for lupus from Biogen, and others such as aficamten, ampreloxetine, ecopipam, olpasiran, pelacarsen, pelabresib, seltorexant, trontinemab, and tulmimetostat. Royalty Pharma conducts its royalty acquisition and funding activities principally in the United States and Europe, with global exposure through its diverse portfolio of international product sales. Founded in 1996 by Pablo Legorreta and Rory B. Riggs and headquartered in New York, New York, the company went public in 2020. Recent developments include the acquisition of a royalty interest in Alnylam's Amvuttra from Blackstone Life Sciences for $310 million in November 2025; a royalty on Amgen's Imdelltra for small cell lung cancer acquired for up to $950 million in 2025; a $2 billion funding arrangement with Revolution Medicines including royalties on daraxonrasib in June 2025; royalties on Rytelo, Niktimvo, Yorvipath, and Voranigo added in 2024; and earlier 2023-2025 transactions such as royalties on obexelimab, litifilimab, Evrysdi, Skytrofa, Adstiladrin, and Cobenfy, reflecting ongoing expansion into oncology, neurology, rare diseases, and synthetic royalty structures.
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma to present at upcoming investor conferences
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Royalty Pharma reports first quarter 2026 results
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation